APTO

Why Aptose Biosciences Stock Sank Today

What happened

Shares of Aptose Biosciences (NASDAQ: APTO) were sinking 13.7% lower as of 3:22 p.m. EDT on Thursday. The decline came after the company announced the pricing of a stock offering Wednesday evening.

So what

Secondary stock offerings typically cause share prices to fall. That makes sense. The addition of new shares dilutes the value of existing shares.

Scientist looking through microscope.

Image source: Getty Images.

Aptose plans to sell 10.5 million new shares at a price of $5.25 per share. The volume of shares being offered represents nearly 14% of the company's total outstanding shares. The price of the offering reflects a 16% discount from the Wednesday closing price of the biotech stock

The good news for Aptose with its stock offering, though, is that it will raise gross proceeds of around $55 million. Even after paying commissions and netting out underwriting discounts and offering expenses, the company will still have plenty of additional cash to fund clinical trials and use for other purposes.

Now what

Aptose's stock offering should close around July 20. The company is currently evaluating two pipeline candidates in phase 1 clinical studies -- CG-806 and APT-253. Aptose expects to expand its study of CG-806 as a potential treatment for B-cell malignancies to include acute myeloid leukemia in the second half of 2020.

10 stocks we like better than Aptose Biosciences
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Aptose Biosciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 2, 2020

 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.